In models of breast and lung cancer, treatment with the selective Axl inhibitor R428 (bemcentinib) in combination with cisplatin resulted in enhanced tumor suppression and delayed metastatic spread compared to monotherapy. This evidence concerns the gene AXL and neoplasm.